Presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet - ProQR Therapeutics
To offer you the best possible service, this site uses functional cookies as well as cookies for web statistics and videos. By clicking "Allow cookies" or continuing to use this website you give us consent to use cookies.
This website uses functional cookies and cookies for web statistics and videos. We do this to provide you with an optimal service. Cookies are small text files that are stored on your device when you visit our website. You can select which cookies you allow so be set in the settings form. By clicking Accept or by continuing to use the website you give your consent to store cookies when you visit the website.
This website uses functional cookies that are required to have a functioning website. We use analytics cookies to optimize the website. You can select which cookies to allow below in the settings.
Published on at Oligonucleotide Therapeutics Society (OTS)
Julien Boudet, Lenka van Sint Fiet, Antti Aalto, Roxana Redis, Tess Hoogeboom, Stephan Freriks, Petra de Bruijn, Lisanne van Wissen, Monika Hiller, Cherie Kemmel, Gerard Platenburg, Janne Turunen and Bart Klein
ProQR Therapeutics, 2333 CK Leiden, The Netherlands.
A robust computational approach is developed to screen for compatible interactions between backbone chemical modifications of EONs and the side-chains of the ADAR2 deaminase domain. Our data have been successfully correlated with docking studies performed with the Autodock Vina program. Experimental results show that the modelled patterns of specific chemical modifications are compatible with enzymatic activity. We demonstrate the applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing. We will extend our structure-based computational tools to other domains of ADARs and combine in silico screening with data from
high-throughput biochemical assays.
Presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet - ProQR Therapeutics
Date:
Author(s): Doherty EE, et al.